May 30 Gilead Sciences Inc said on
Tuesday its combination treatment for HIV met the main goal in
four late-stage studies, paving the way for regulatory
The company is testing bictegravir in combination with
emtricitabine/tenofovir alafenamide (FTC/TAF) in the trials.
"This investigational single tablet regimen brings together
the potency of...bictegravir, with the demonstrated efficacy and
safety profile of the FTC/TAF backbone," said Norbert
Bischofberger, Gilead's Chief Scientific Officer.
The company said it planned to submit applications for
approvals in the United States and the EU this year.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by